Tumor-specific biology, diagnosis, and therapy

Pediatric high-grade gliomas (pHGGs) and diffuse midline gliomas (DMGs) represent some of the most aggressive and lethal childhood brain tumors. Recent molecular and epigenetic discoveries have redefined these entities as distinct from adult gliomas, with hallmark alterations such as H3K27M and H3G34R/V mutation driving unique biological behaviors. Advances in genomic, epigenomic, and transcriptomic profiling have enabled refined diagnostic classifications, improved our understanding of tumor heterogeneity, and revealed novel therapeutic targets. Despite these insights, standard of care approaches-primarily radiotherapy-remain palliative and conventional chemotherapy has shown limited efficacy. Emerging strategies, including targeted molecular therapies, immunotherapies, and innovative drug delivery techniques, offer promise but face significant challenges related to blood-brain barrier integrity, immune evasion, and intratumoral heterogeneity. Integration of DNA methylation profiling, enhancer landscape analysis, and liquid biopsy technologies are transforming diagnostic and monitoring capabilities. Future progress will depend on interdisciplinary collaboration, the development of predictive preclinical models, multi-omic integration, and adaptive clinical trial designs. Ultimately, tackling the biological complexity of pHGGs and DMGs through personalized, molecularly targeted approaches offers the best hope for improving outcomes in this devastating disease group.